Sign in or create an account to add this stock to your watchlist.
About NewLink Genetics (NASDAQ:NLNK)
NewLink Genetics Corporation, a late clinical-stage immuno-oncology company, focuses on discovering and developing novel immunotherapeutic products for the treatment of patients with cancer. It is developing NLG2103, a combination of indoximod and standard of care checkpoint inhibitors, which is in Phase II clinical trial for treating patients with advanced melanoma; and Indigo301, a combination of indoximod with a checkpoint inhibitor that is in Phase III clinical trial for treating patients with advanced unresectable or metastatic melanoma, as well as combination of indoximod with other cancer therapeutics for patients with melanoma, pancreatic cancer, pediatric brain tumors, and acute myeloid leukemia. The company is also developing NLG802, a prodrug of indoximod, which has completed Phase I clinical trial; and NLG919, a clinical stage indoleamine-2, 3-dioxygenase pathway inhibitor. In addition, it is developing tergenpumatucel-L and dorgenmeltucel-L that are in Phase II clinical trials for treating patients with advanced lung cancer and melanoma; and CRLX101 and CRLX301, which are in early clinical development to treat patients with advanced solid malignancies. The company has strategic collaboration agreement with AstraZeneca to evaluate the combination of indoximod and durvalumab, an anti-PD-L1 monoclonal antibody for treating patients with metastatic pancreatic cancer; Genentech Inc. for the development and commercialization of NLG919, as well as a research collaboration for the discovery of next generation IDO/TDO inhibitors; and Merck Sharpe and Dohme Corp. to research, develop, and commercialize rVSV G-ZEBOV GP, an Ebola vaccine product candidate. NewLink Genetics Corporation was founded in 1999 and is headquartered in Ames, Iowa.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
SymbolNASDAQ:NLNK
CUSIP65151110
Phone515-296-5555
Debt
Debt-to-Equity RatioN/A
Current Ratio8.01
Quick Ratio8.01
Price-To-Earnings
Trailing P/E Ratio-2.32
Forward P/E Ratio-2.46
P/E GrowthN/A
Sales & Book Value
Annual Sales$28.71 million
Price / Sales6.90
Cash FlowN/A
Price / CashN/A
Book Value$3.71 per share
Price / Book1.44
Profitability
EPS (Most Recent Fiscal Year)($2.30)
Net Income$-71,950,000.00
Net Margins-193.44%
Return on Equity-55.64%
Return on Assets-44.63%
Miscellaneous
Employees76
Outstanding Shares37,170,000
NewLink Genetics (NASDAQ:NLNK) Frequently Asked Questions
What is NewLink Genetics' stock symbol?
NewLink Genetics trades on the NASDAQ under the ticker symbol "NLNK."
How were NewLink Genetics' earnings last quarter?
NewLink Genetics Co. (NASDAQ:NLNK) posted its earnings results on Thursday, May, 3rd. The biotechnology company reported ($0.49) earnings per share for the quarter, topping the Zacks' consensus estimate of ($0.55) by $0.06. The biotechnology company had revenue of $9.90 million for the quarter, compared to analyst estimates of $5.78 million. NewLink Genetics had a negative net margin of 193.44% and a negative return on equity of 55.64%. View NewLink Genetics' Earnings History.
When is NewLink Genetics' next earnings date?
What price target have analysts set for NLNK?
6 brokers have issued twelve-month price objectives for NewLink Genetics' stock. Their predictions range from $5.00 to $25.00. On average, they expect NewLink Genetics' stock price to reach $11.3333 in the next year. View Analyst Ratings for NewLink Genetics.
What are Wall Street analysts saying about NewLink Genetics stock?
Here are some recent quotes from research analysts about NewLink Genetics stock:
- 1. According to Zacks Investment Research, "NewLink Genetics Corporation is a biopharmaceutical company which focuses on discovering, developing and commercializing immunotherapeutic products for cancer treatment. Its portfolio also includes biologic and small-molecule immunotherapy products used for the treatment of oncology indications. NewLink Genetics Corporation is headquartered in Ames, Iowa. " (5/5/2018)
- 2. Cantor Fitzgerald analysts commented, "Data from a Phase I study of indoximod in diffuse intrinsic pontine glioma (DIPG) presented at AACR were positive, in our view, but given the recent failure of Incyte’s (INCY, NC) epacadostat, we do not believe that is likely to sway investors at this point." (4/16/2018)
Who are some of NewLink Genetics' key competitors?
Some companies that are related to NewLink Genetics include Vectura Group (VEGPF), Rocket Pharmaceuticals (RCKT), GlycoMimetics (GLYC), Homology Medicines (FIXX), CymaBay Therapeutics (CBAY), Dova Pharmaceuticals (DOVA), ANI Pharmaceuticals Inc Common Stock (ANIP), Dicerna Pharmaceuticals (DRNA), Arcus Biosciences (RCUS), Geron (GERN), BeyondSpring (BYSI), Five Prime Therapeutics (FPRX), Rigel Pharmaceuticals (RIGL), Lannett (LCI) and Odonate Therapeutics (ODT).
Who are NewLink Genetics' key executives?
NewLink Genetics' management team includes the folowing people:
- Mr. Charles J. Link Jr., Co-Founder, Chairman, CEO & Chief Scientific Officer (Age 59)
- Mr. Nicholas N. Vahanian M.D., Co-Founder, Pres, Chief Medical Officer & Director (leave of absence) (Age 51)
- Mr. John B. Henneman III, CFO & Sec. (Age 56)
- Mr. Carl W. Langren, VP of Fin. & Principal Accounting Officer (Age 63)
- Mr. Brian Wiley, Chief Commercial Officer (Age 50)
Has NewLink Genetics been receiving favorable news coverage?
News headlines about NLNK stock have been trending somewhat positive on Thursday, Accern Sentiment reports. Accern identifies negative and positive press coverage by monitoring more than twenty million blog and news sources in real time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. NewLink Genetics earned a daily sentiment score of 0.15 on Accern's scale. They also gave news headlines about the biotechnology company an impact score of 47.21 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company's share price in the next several days.
Who are NewLink Genetics' major shareholders?
NewLink Genetics' stock is owned by many different of retail and institutional investors. Top institutional shareholders include 1GLOBE CAPITAL LLC Total Shares: 2,589,513 (6.97%), First Eagle Investment Management LLC (6.31%), BlackRock Inc. (6.08%), Redmile Group LLC (5.53%), JPMorgan Chase & Co. (1.33%) and Wells Fargo & Company MN (1.11%). Company insiders that own NewLink Genetics stock include Carl W Langren and Stine Seed Farm, Inc. View Institutional Ownership Trends for NewLink Genetics.
Which major investors are selling NewLink Genetics stock?
Which major investors are buying NewLink Genetics stock?
NLNK stock was bought by a variety of institutional investors in the last quarter, including JPMorgan Chase & Co., Arnhold LLC, Alambic Investment Management L.P., Wells Fargo & Company MN and Schwab Charles Investment Management Inc.. View Insider Buying and Selling for NewLink Genetics.
How do I buy shares of NewLink Genetics?
Shares of NLNK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is NewLink Genetics' stock price today?
One share of NLNK stock can currently be purchased for approximately $5.33.
How big of a company is NewLink Genetics?
NewLink Genetics has a market capitalization of $193.26 million and generates $28.71 million in revenue each year. The biotechnology company earns $-71,950,000.00 in net income (profit) each year or ($2.30) on an earnings per share basis. NewLink Genetics employs 76 workers across the globe.
How can I contact NewLink Genetics?
NewLink Genetics' mailing address is 2503 SOUTH LOOP DRIVE SUITE 5100, AMES IA, 50010. The biotechnology company can be reached via phone at 515-296-5555 or via email at [email protected]
MarketBeat Community Rating for NewLink Genetics (NLNK)
MarketBeat's community ratings are surveys of what our community members think about NewLink Genetics and other stocks. Vote "Outperform" if you believe NLNK will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NLNK will underperform the S&P 500 over the long term. You may vote once every thirty days.
NewLink Genetics (NASDAQ:NLNK) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
6 Wall Street analysts have issued ratings and price targets for NewLink Genetics in the last 12 months. Their average twelve-month price target is $11.3333, suggesting that the stock has a possible upside of 112.63%. The high price target for NLNK is $25.00 and the low price target for NLNK is $5.00. There are currently 5 hold ratings and 1 buy rating for the stock, resulting in a consensus rating of "Hold."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Hold | Hold | Buy | Buy |
| Consensus Rating Score: | 2.17 | 2.17 | 3.00 | 3.00 |
| Ratings Breakdown: | 0 Sell Rating(s)
5 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
5 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $11.3333 | $13.50 | $25.6667 | $25.6667 |
| Price Target Upside: | 112.63% upside | 202.01% upside | 203.57% upside | 174.22% upside |
NewLink Genetics (NASDAQ:NLNK) Consensus Price Target History
NewLink Genetics (NASDAQ:NLNK) Analyst Ratings History
Show:
(Data available from 5/24/2016 forward)
NewLink Genetics (NASDAQ:NLNK) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
NewLink Genetics (NASDAQ NLNK) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 12.30%
Institutional Ownership Percentage: 53.04%
NewLink Genetics (NASDAQ NLNK) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 11/21/2017 | Carl W. Langren | Insider | Sell | 2,229 | $9.05 | $20,172.45 | |  |
| 10/6/2017 | Stine Seed Farm, Inc. | Major Shareholder | Buy | 780,487 | $10.25 | $7,999,991.75 | 7,857,732 | |
| 3/15/2016 | Charles J Jr. Link | CEO | Sell | 25,000 | $17.86 | $446,500.00 | 297,756 | |
| 1/6/2016 | Charles J. Jr. Link | CEO | Sell | 25,000 | $32.53 | $813,250.00 | 342,756 | |
| 1/5/2016 | Brian Wiley | VP | Sell | 1,295 | $34.99 | $45,312.05 | 19,942 | |
| 1/5/2016 | Carl W. Langren | insider | Sell | 1,095 | $34.97 | $38,292.15 | 13,465 | |
| 1/5/2016 | Charles J. Jr. Link | CEO | Sell | 5,001 | $35.06 | $175,335.06 | 342,756 | |
| 1/5/2016 | John B. Henneman III | CFO | Sell | 175 | $35.74 | $6,254.50 | 62,316 | |
| 10/7/2015 | Charles J. Jr. Link | CEO | Sell | 10,000 | $35.16 | $351,600.00 | 371,118 | |
| 10/5/2015 | Charles J. Jr. Link | CEO | Sell | 15,000 | $37.36 | $560,400.00 | 371,118 | |
| 7/13/2015 | Joseph Saluri | Director | Sell | 5,000 | $50.42 | $252,100.00 | | |
| 7/6/2015 | Charles J Jr. Link | CEO | Sell | 20,000 | $44.65 | $893,000.00 | | |
(Data available from 1/1/2013 forward)
NewLink Genetics (NASDAQ NLNK) News Headlines
| Source: |
|
| Date | Headline |
|---|
 | Brokerages Expect NewLink Genetics Co. (NLNK) Will Post Quarterly Sales of $5.85 Million
www.americanbankingnews.com - May 22 at 3:44 AM |
| NewLink Genetics Co. (NLNK) Given Consensus Rating of "Hold" by Brokerages
www.americanbankingnews.com - May 21 at 1:47 PM |
| Zacks: Analysts Expect NewLink Genetics Co. (NLNK) Will Post Earnings of -$0.58 Per Share
www.americanbankingnews.com - May 20 at 1:26 PM |
 | NewLink Genetics: Explicating The Changing Fundamentals Of A Potential Comeback
seekingalpha.com - May 17 at 8:22 AM |
 | NewLink Genetics Announces Final Results from Phase 2 Studies of Indoximod in Advanced Melanoma and Metastatic Pancreatic Cancer to be Presented at ASCO 2018
finance.yahoo.com - May 16 at 5:41 PM |
| Roche backs out of IDO inhibitor development deal with NewLink
seekingalpha.com - May 15 at 5:48 PM |
| NewLink Genetics (NLNK) Lowered to "Strong Sell" at ValuEngine
www.americanbankingnews.com - May 8 at 3:29 PM |
 | BRIEF-Newlink Genetics Corp Reports Qtrly Loss Per Share Of $0.49
www.reuters.com - May 5 at 5:41 PM |
| NewLink Genetics (NLNK) Upgraded to Buy at Zacks Investment Research
www.americanbankingnews.com - May 5 at 6:37 AM |
| Zacks: Brokerages Anticipate NewLink Genetics Co. (NLNK) Will Announce Quarterly Sales of $4.79 Million
www.americanbankingnews.com - May 5 at 5:05 AM |
| NewLink Genetics (NLNK) Given a $7.00 Price Target at Cantor Fitzgerald
www.americanbankingnews.com - May 4 at 10:31 PM |
| NewLink Genetics (NLNK) Announces Earnings Results, Beats Estimates By $0.06 EPS
www.americanbankingnews.com - May 4 at 9:33 PM |
| NewLink Genetics (NLNK) Given New $8.00 Price Target at Stifel Nicolaus
www.americanbankingnews.com - May 4 at 7:03 PM |
| NewLink Genetics' (NLNK) CEO Charles Link on Q1 2018 Results - Earnings Call Transcript
seekingalpha.com - May 4 at 8:19 AM |
| NewLink: 1Q Earnings Snapshot
finance.yahoo.com - May 4 at 8:19 AM |
| Edited Transcript of NLNK earnings conference call or presentation 3-May-18 8:30pm GMT
finance.yahoo.com - May 4 at 8:19 AM |
| NewLink Genetics beats by $0.06, beats on revenue
seekingalpha.com - May 3 at 5:24 PM |
| NewLink Genetics Reports First Quarter 2018 Financial Results
finance.yahoo.com - May 3 at 5:24 PM |
| -$0.55 EPS Expected for NewLink Genetics Co. (NLNK) This Quarter
www.americanbankingnews.com - May 3 at 1:18 AM |
| NewLink Genetics (NLNK) Upgraded to Sell by ValuEngine
www.americanbankingnews.com - May 2 at 11:06 PM |
| NewLink Genetics Appoints Matthew L. Sherman, M.D. to Board of Directors
finance.yahoo.com - May 1 at 5:18 PM |
| NewLink Genetics Corp (NLNK) Receives Consensus Recommendation of "Hold" from Analysts
www.americanbankingnews.com - April 26 at 1:42 PM |
| NewLink Genetics (NLNK) Scheduled to Post Quarterly Earnings on Thursday
www.americanbankingnews.com - April 26 at 4:08 AM |
| NewLink Genetics Announces Presentation of Abstracts at ASCO 2018 Annual Meeting
finance.yahoo.com - April 25 at 5:28 PM |
| NewLink Genetics to Host Its First Quarter 2018 Financial Results Conference Call on May 3, 2018
finance.yahoo.com - April 20 at 5:21 PM |
| NewLink Genetics (NLNK) Downgraded to Sell at Zacks Investment Research
www.americanbankingnews.com - April 18 at 8:34 PM |
| NewLink Genetics Describes the Differentiated Mechanism of Action of Indoximod in AACR Poster Presentation
finance.yahoo.com - April 17 at 5:54 PM |
| Zacks: Analysts Expect NewLink Genetics Corp (NLNK) Will Post Quarterly Sales of $5.78 Million
www.americanbankingnews.com - April 17 at 1:50 AM |
| NewLink down 8% after bailing on indoximod in melanoma study
seekingalpha.com - April 16 at 5:24 PM |
 | Early data indicate indoximod has clinical activity when used in combination therapies beyond PD-1 inhibition
globenewswire.com - April 16 at 8:16 AM |
| NewLink Genetics' (NLNK) Hold Rating Reaffirmed at Cantor Fitzgerald
www.americanbankingnews.com - April 16 at 7:11 AM |
| Analysts Anticipate NewLink Genetics Corp (NLNK) Will Announce Earnings of -$0.55 Per Share
www.americanbankingnews.com - April 15 at 11:10 PM |
 | NewLink Genetics Announces Initial Phase 1 Data with Indoximod Plus Radiation and Chemotherapy for
www.nasdaq.com - April 15 at 6:35 PM |
| Jefferies Group Reiterates "Hold" Rating for NewLink Genetics (NLNK)
www.americanbankingnews.com - April 12 at 11:17 AM |
| NewLink Genetics' Potential Catalysts Not Enough To Justify A Bullish Stance, Baird Says In Downgrade
finance.yahoo.com - April 10 at 8:27 AM |
| NewLink Shares Plunge After Incyte & Merck's Study Fails
finance.yahoo.com - April 10 at 8:27 AM |
| New Research Coverage Highlights Golden Star Resources, Ryanair, Sasol, Access National, NewLink Genetics, and Canadian Pacific Railway — Consolidated Revenues, Company Growth, and Expectations for 2018
finance.yahoo.com - April 10 at 8:27 AM |
 | NewLink Shares Plunge After Incyte & Merck's Study Fails
www.zacks.com - April 9 at 5:21 PM |
 | UPDATE: Baird Downgrades NewLink Genetics (NLNK) to Neutral Citing IDO Concerns
www.streetinsider.com - April 9 at 5:21 PM |
| UPDATE: Cantor Fitzgerald Downgrades NewLink Genetics (NLNK) to Neutral
www.streetinsider.com - April 9 at 5:21 PM |
| NewLink Genetics (NLNK) Rating Lowered to Hold at Robert W. Baird
www.americanbankingnews.com - April 9 at 7:55 AM |
| NewLink Genetics (NLNK) Lowered to "Hold" at Cantor Fitzgerald
www.americanbankingnews.com - April 9 at 7:55 AM |
| SunTrust Robinson Humphrey Downgrades NewLink Genetics (NLNK) to Hold
www.streetinsider.com - April 7 at 8:25 AM |
| NewLink Genetics (NLNK) Downgraded by Jefferies Group to "Hold"
www.americanbankingnews.com - April 6 at 9:16 PM |
 | NewLink Genetics shares plummet 39% after Merck, Incyte trial failure
www.marketwatch.com - April 6 at 5:41 PM |
| Incyte's late-stage epacadostat flop pressures NewLink Genetics, down 32% premarket
seekingalpha.com - April 6 at 5:41 PM |
| NewLink Genetics Announces Review of Clinical Programs
www.nasdaq.com - April 6 at 5:41 PM |
| Why Incyte and NewLink Genetics Crashed Today
finance.yahoo.com - April 6 at 5:41 PM |
| NewLink Genetics (NLNK) Lowered to "Neutral" at Bank of America
www.americanbankingnews.com - April 6 at 4:14 PM |
| SunTrust Banks Downgrades NewLink Genetics (NLNK) to Hold
www.americanbankingnews.com - April 6 at 1:23 PM |
NewLink Genetics (NASDAQ:NLNK) SEC Filings
This page is loading this company's SEC Filings. Please wait...
NewLink Genetics (NASDAQ:NLNK) Income Statement, Balance Sheet and Cash Flow Statement
NewLink Genetics (NASDAQ NLNK) Stock Chart for Thursday, May, 24, 2018
Loading chart…
